Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2017

View Archived Issues

Promius Pharma's phase II study of intranasal sumatriptan meets primary endpoint

Biomarkers predict success of Tessa Therapeutics CTL immunotherapy in nasopharyngeal cancer

Subcutaneous Orencia available for patients 2 years of age and older

Genentech returning rights to GDC-0919 to NewLink Genetics

Cascadian Therapeutics' tucatinib receives FDA orphan drug designation

FDA grants fast track status to Aeolus Pharmaceuticals' AEOL-10150

Meiji Seika Pharma's TS-3112 shows promise against antibiotic-resistant bacteria

Valeant enters agreement to sell iNova Pharmaceuticals

2X Oncology obtains IND application for 2X-111 from 2-BBB Medicines

Upadacitinib meets all primary and secondary endpoints in phase III SELECT-NEXT study

TSRI and ShangPharma Innovation enter translational research collaboration

Chitinase inhibitor OAT-889 effective in models of airway inflammation

FDA grants orphan drug status to tavokinogene telsaplasmid in unresectable metastatic melanoma

FDA requests removal of Opana ER from the market

Inovio Pharmaceuticals initiates REVEAL phase III program for VGX-3100

Iproteos discovers novel matrix metalloproteinase-2/9 inhibitors

Merck & Co. describes new oxysterols receptor LXR-beta agonists

Sensorion announces positive phase I results for SENS-401

Vitros NephroCheck test becomes available in Europe

Lilly and KeyBioscience enter strategic collaboration

Wakunaga Pharmaceutical's WFQ-228 and WFQ-253 show promise for hospital-acquired pneumonia

Burtomab granted breakthrough therapy designation for advanced form of pediatric neuroblastoma

Kissei gains exclusive rights to develop and commercialize avacopan in Japan

Eureka Therapeutics and City of Hope enter agreement for phase I clinical testing of ET1402L1 CAR-T

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...